Hope for Heavily Pretreated NSCLC is Provided by Novel ADC.

Published Date: 12 Sep 2023

A novel antibody-drug conjugate called HER3-DXd may provide meaningful and long-lasting responses in patients with EGFR-mutated NSCLC who have progressed after receiving multiple lines of therapy, according to new phase 2 data.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

How access to specialized cancer centers affects glioblastoma outcomes

2.

Cancer Patients Who Completed Medication Survey Received More Help From Pharmacists

3.

Positive Trials; Malignancies Increasing in Younger Adults; Andre Braugher's Cancer Dx.

4.

U.S. Nurse Found Dead; Harvey Weinstein's Cancer; Creepy Source of Ear Pain

5.

Beyond What Is Visible in Myelofibrosis?


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot